Canada markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.32+0.02 (+0.24%)
At close: 04:00PM EST
8.39 +0.07 (+0.84%)
After hours: 05:12PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

    – AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent cellular phagocytosis (ADCP) activity –– Allakos plans to initiate the first-in-human study of AK006 during 1H 2023 – SAN CARLOS, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory recept

  • GlobeNewswire

    Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

    – Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 –– Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-associated myeloid cells and reduced tumor burden in pre-clinical studies – SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology co

  • GlobeNewswire

    Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

    SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Recent Allakos Events Allakos’s lirentelimab clinical development is focused on atopic dermatitis and chronic spontaneous urticaria. Initiated a Phase 2b randomized,